Barra Fabio, Laganà Antonio Simone, Ghezzi Fabio, Casarin Jvan, Ferrero Simone
Department of Neurosciences, Rehabilitation, Ophthalmology, Genetics, Maternal and Child Health (DiNOGMI), University of Genova, Genova, Italy.
Academic Unit of Obstetrics and Gynecology, IRCCS Ospedale Policlinico San Martino, Genova, Italy.
Gynecol Obstet Invest. 2019;84(2):107-117. doi: 10.1159/000493361. Epub 2018 Oct 10.
BACKGROUND/AIMS: Epithelial ovarian cancer (EOC) is the sixth most commonly diagnosed cancer among women. Results with available therapies are far from being satisfactory and, therefore, current research is focusing on new anticancer drugs to improve the clinical response of these patients. Nintedanib is an oral multiple tyrosine kinases inhibitor, which targets angiogenesis. Considering the current scenario, the aim of this systematic review is to highlight the prevailing knowledge about pharmacokinetics, pharmacodynamics, clinical efficacy, and safety of Nintedanib for the treatment of advanced EOC.
We performed a systematic review of the literature, screening all available articles about the treatment of advanced EOC with Nintedanib, including phase I, II, and III trials.
Although in early phase clinical trials, Nintedanib has demonstrated anticancer activity and tolerability as monotherapy or in combination with carboplatin and paclitaxel. In the phase III trial AGO-OVAR 12, it obtained a modest improvement in progression-free survival (PFS) as first-line combination therapy for patients with advanced EOC. Interestingly, a PFS increase was observed in patients with non-high progression risk or low tumor burden.
Despite the promising results, further studies are needed to evaluate Nintedanib efficacy in women affected by EOC.
背景/目的：上皮性卵巢癌（EOC）是女性中第六大最常被诊断出的癌症。现有治疗方法的效果远不能令人满意，因此，当前的研究集中在新型抗癌药物上，以改善这些患者的临床反应。尼达尼布是一种口服多酪氨酸激酶抑制剂，靶向血管生成。考虑到当前的情况，本系统评价的目的是突出关于尼达尼布治疗晚期EOC的药代动力学、药效学、临床疗效和安全性的现有知识。
我们对文献进行了系统评价，筛选了所有关于尼达尼布治疗晚期EOC的可用文章，包括I期、II期和III期试验。
尽管在早期临床试验中，尼达尼布作为单一疗法或与卡铂和紫杉醇联合使用已显示出抗癌活性和耐受性。在III期试验AGO-OVAR 12中，作为晚期EOC患者的一线联合疗法，它在无进展生存期（PFS）方面有适度改善。有趣的是，在非高进展风险或低肿瘤负荷的患者中观察到PFS增加。
尽管结果令人鼓舞，但仍需要进一步研究来评估尼达尼布对EOC女性患者的疗效。
